Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
Revenue
Interpace Biosciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Interpace Biosciences Inc
OTC:IDXG
|
Revenue
$38.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-13%
|
|
DaVita Inc
NYSE:DVA
|
Revenue
$12.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Revenue
$9.3B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
CVS Health Corp
NYSE:CVS
|
Revenue
$357.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
Cigna Corp
NYSE:CI
|
Revenue
$195.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
32%
|
CAGR 10-Years
20%
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Revenue
$12.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
See Also
What is Interpace Biosciences Inc's Revenue?
Revenue
38.2m
USD
Based on the financial report for Sep 30, 2023, Interpace Biosciences Inc's Revenue amounts to 38.2m USD.
What is Interpace Biosciences Inc's Revenue growth rate?
Revenue CAGR 10Y
-13%
Over the last year, the Revenue growth was 17%. The average annual Revenue growth rates for Interpace Biosciences Inc have been 12% over the past three years , 13% over the past five years , and -13% over the past ten years .